X0508 4 2025-05-15 0001744659 Akero Therapeutics, Inc. AKRO 0001779308 Yale Catriona 601 GATEWAY BOULEVARD SUITE 350 SOUTH SAN FRANCISCO CA 94080 false true false false Chief Development Officer true Common Stock 2025-05-15 4 M false 10000 21.1 A 105034 D Common Stock 2025-05-15 4 S false 2837 38.199 D 102197 D Common Stock 2025-05-15 4 S false 2779 39.46 D 99418 D Common Stock 2025-05-15 4 S false 4384 39.906 D 95034 D Stock Option (Right to Buy) 21.1 2025-05-15 4 M false 10000 0 D 2031-12-07 Common Stock 29073 10000 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 24, 2024, previously adopted by the Reporting Person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.70 to $38.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.76 to $39.71, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.77 to $40.13, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The options are vested and currently exercisable. /s/ Jonathan Young, Attorney-in-Fact 2025-05-19